BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24599679)

  • 1. Late-onset neutropenia following rituximab treatment for rheumatologic conditions.
    Breuer GS; Ehrenfeld M; Rosner I; Balbir-Gurman A; Zisman D; Oren S; Paran D
    Clin Rheumatol; 2014 Sep; 33(9):1337-40. PubMed ID: 24599679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center.
    Besada E; Koldingsnes W; Nossent J
    QJM; 2012 Jun; 105(6):545-50. PubMed ID: 22301823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
    Wolach O; Bairey O; Lahav M
    Medicine (Baltimore); 2010 Sep; 89(5):308-318. PubMed ID: 20827108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab.
    Abdulkader R; Dharmapalaiah C; Rose G; Shand LM; Clunie GP; Watts RA
    J Rheumatol; 2014 May; 41(5):858-61. PubMed ID: 24634201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.
    Tesfa D; Ajeganova S; Hägglund H; Sander B; Fadeel B; Hafström I; Palmblad J
    Arthritis Rheum; 2011 Aug; 63(8):2209-14. PubMed ID: 21560117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.
    Monaco WE; Jones JD; Rigby WF
    Clin Rheumatol; 2016 Oct; 35(10):2457-62. PubMed ID: 27209045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature.
    Guidelli GM; Fioravanti A; Rubegni P; Feci L
    Rheumatol Int; 2013 Nov; 33(11):2927-30. PubMed ID: 23135613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL.
    Parodis I; Söder F; Faustini F; Kasza Z; Samuelsson I; Zickert A; Svenungsson E; van Vollenhoven RF; Malmström V; Wermeling F; Gunnarsson I
    Lupus; 2018 Aug; 27(9):1470-1478. PubMed ID: 29783918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutropenia after rituximab treatment: new insights on a late complication.
    Wolach O; Shpilberg O; Lahav M
    Curr Opin Hematol; 2012 Jan; 19(1):32-8. PubMed ID: 22080846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Late-onset neutropenia following rituximab therapy as a treatment of diffuse large B-cell lymphoma: a single institution study].
    Kim M; Lee JK; Hong YJ; Hong SI; Kang HJ; Chang YH
    Korean J Lab Med; 2010 Dec; 30(6):575-9. PubMed ID: 21157141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.
    Tesfa D; Gelius T; Sander B; Kimby E; Fadeel B; Palmblad J; Hägglund H
    Med Oncol; 2008; 25(4):374-9. PubMed ID: 18278570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.
    Zonozi R; Wallace ZS; Laliberte K; Huizenga NR; Rosenthal JM; Rhee EP; Cortazar FB; Niles JL
    Arthritis Rheumatol; 2021 Feb; 73(2):347-354. PubMed ID: 32892495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy.
    Rozman S; Sonc M; Novakovic BJ
    Leuk Lymphoma; 2012 Oct; 53(10):1945-8. PubMed ID: 22563814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study.
    Nitta E; Izutsu K; Sato T; Ota Y; Takeuchi K; Kamijo A; Takahashi K; Oshima K; Kanda Y; Chiba S; Motokura T; Kurokawa M
    Ann Oncol; 2007 Feb; 18(2):364-9. PubMed ID: 17079695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms.
    Tesfa D; Palmblad J
    Expert Rev Hematol; 2011 Dec; 4(6):619-25. PubMed ID: 22077526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review.
    Hirai Y; Ainoda Y; Shoji T; Fujita T; Yoshinaga K; Shiseki M; Mori N; Teramura M; Totsuka K; Motoji T
    Mycopathologia; 2011 Sep; 172(3):227-32. PubMed ID: 21472389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutropenia associated with rituximab therapy.
    Grant C; Wilson WH; Dunleavy K
    Curr Opin Hematol; 2011 Jan; 18(1):49-54. PubMed ID: 21102324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma.
    Aguiar-Bujanda D; Blanco-Sánchez MJ; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura-Grau S; Bohn-Sarmiento U
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):761-5. PubMed ID: 26319620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
    Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
    Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.